Tracked deals
11
11 tracked deals across 2019-2025.
Private Equity Firm
Healthcare
1315 Capital
Philadelphia, Pennsylvania, United States
1315 Capital provides expansion and growth capital to commercial-stage healthcare services, medical technology, medtech & pharma outsourcing, and health & wellness companies.
- Focus Areas
- Healthcare services, Medical technology (medtech), Pharma outsourcing
- Website
- 1315capital.com
Recent pace
0
0 tracked deals announced in the last 12 months.
Deal mix
Growth capital
7 growth capital · 2 buyout · 2 divestiture
1315 Capital Acquisition Volume by Year
Last 6 years
Supporting Data
Recent Transactions
-
- Buyer
- 1315 Capital
- Target
- USpharma Ltd.
- Industry
- Pharmaceuticals
- Location
- Florida, United States
- Type
- Growth capital
USpharma Ltd., a Miami Lakes-based pharmaceutical development and manufacturing company, received a growth equity investment from Philadelphia-based 1315 Capital. The capital will be used to accelerate development and commercialization of USpharma’s pipeline, expand commercial reach, and scale operations at its 150,000 sq. ft. US-based GMP facility.
-
November 14, 2024
- Buyer
- 1315 Capital
- Target
- SciSafe
- Seller
- BioLife Solutions, Inc.
- Industry
- Healthcare Services
- Location
- New Jersey, United States
- Type
- Divestiture
1315 Capital, a Philadelphia-based growth equity firm, has acquired SciSafe from BioLife Solutions in an all-cash transaction that establishes SciSafe as an independent, standalone biostorage company. The deal accompanies a growth capital investment to fund expansion of SciSafe's biostorage, cold-chain and compliance capabilities and to support global footprint growth.
-
October 29, 2024
- Buyer
- 1315 Capital, East Seattle Partners, Harro Höfliger Packaging Systems, Inc., Kineticos Ventures
- Target
- Experic
- Industry
- Pharmaceuticals
- Location
- New Jersey, United States
- Type
- Growth capital
Experic, a Cranbury, New Jersey-based CDMO and clinical trial supply services firm, received a growth capital investment led by 1315 Capital with participation from existing investors East Seattle Partners, Harro Höfliger Packaging Systems, Inc., and Kineticos Ventures. The capital will be used to enhance Experic’s manufacturing capabilities and accelerate its international expansion to better serve biopharmaceutical clients.
-
June 17, 2024
- Buyer
- 1315 Capital
- Target
- Primrose Bio, Inc.
- Industry
- Biotechnology
- Location
- California, United States
- Type
- Growth capital
1315 Capital, a Philadelphia-based healthcare-focused growth equity firm, made a significant equity investment in Primrose Bio to support development and commercial expansion of Primrose’s nucleic acid and protein manufacturing technologies. The funding will accelerate commercialization of the company’s Prima RNApols, Pfenex expression system, and PeliCRM carrier protein for therapeutics and vaccines.
-
February 1, 2024
- Buyer
- 1315 Capital
- Target
- Triple Ring Technologies
- Industry
- Healthcare Services
- Location
- California, United States
- Type
- Growth capital
1315 Capital, a Philadelphia-based healthcare growth equity firm, made a growth capital investment in Triple Ring Technologies, a Silicon Valley-based medical device and life sciences co-development and engineering services company. The investment will accelerate Triple Ring's geographic expansion and extension of its R&D and product development services to scale its engineering and outsourced R&D services platform.
-
October 4, 2022
- Buyer
- 1315 Capital, John Martin
- Target
- Innovative ECMO Concepts
- Industry
- Healthcare Services
- Location
- Texas, United States
- Type
- Growth capital
Innovative ECMO Concepts received a growth capital investment from 1315 Capital and John Martin, who was also named CEO. The funding will support expansion of the company's ECMO staffing, on-demand training, and patient transport services to increase ECMO capacity at hospitals and broaden access to ECLS.
-
September 30, 2021
- Buyer
- 1315 Capital, MoonSail Capital
- Target
- Homestead Smart Health Plans
- Industry
- Healthcare Services
- Location
- Pennsylvania, United States
- Type
- Buyout
Philadelphia-based 1315 Capital has acquired a majority interest in Homestead Smart Health Plans, a reference-based pricing and third-party administration specialist, with participation from MoonSail Capital. The investors will provide growth capital to help Homestead scale its proprietary platform and expand its employer-focused cost-containment solutions nationally; Homestead CEO Bill Green will remain in place.
-
June 11, 2021
- Buyer
- 1315 Capital
- Target
- miraDry
- Seller
- Sientra, Inc.
- Industry
- Medical Devices
- Location
- California, United States
- Type
- Divestiture
1315 Capital, a healthcare growth equity firm, has acquired the miraDry business from Sientra, enabling Sientra to focus on its core Breast Products business. The transaction transfers ownership of the miraDry FDA-cleared sweat-reduction device and related business to 1315 Capital, which plans to invest in service, support, training and global expansion.
-
September 10, 2020
- Buyer
- 1315 Capital
- Target
- ProSciento, Inc.
- Industry
- Healthcare Services
- Location
- California, United States
- Type
- Growth capital
ProSciento, a San Diego–based specialty clinical research organization focused on NASH, diabetes and obesity, closed a growth financing round with healthcare investor 1315 Capital. The capital will support expansion of ProSciento's CRO operations and growth of its patient access solutions, including the NASH PASS registry.
-
- Buyer
- 1315 Capital, Ampersand Capital Partners
- Target
- Interpace Biosciences, Inc.
- Industry
- Healthcare Services
- Location
- New Jersey, United States
- Type
- Growth capital
Interpace Biosciences entered into an agreement for a $20 million Series B Preferred Stock investment — $19 million from 1315 Capital and $1 million from existing investor Ampersand Capital Partners. The financing (and a coincident one-for-ten reverse stock split) is intended to help Interpace reach cash-flow break-even, accelerate growth and pursue acquisitions; Ampersand also exchanged its Series A preferred for the new Series B shares.
-
January 16, 2019
- Buyer
- 1315 Capital
- Target
- Biocoat, Inc.
- Industry
- Medical Devices
- Location
- Pennsylvania, United States
- Type
- Buyout
Philadelphia-based healthcare investment firm 1315 Capital has acquired Biocoat, Inc., a Horsham, Pennsylvania specialty manufacturer of hydrophilic biomaterial coatings for medical devices; the transaction closed on December 20, 2018. 1315 Capital's investment will provide expansion and growth capital to accelerate R&D, expand Biocoat's operating model, and support broader commercial efforts across neurovascular, cardiovascular, peripheral, and ophthalmic end markets.
Related Acquisition Pages
Healthcare Services Buyers & Acquisitions
6 tracked deals by 1315 Capital.
Medical Devices Buyers & Acquisitions
2 tracked deals by 1315 Capital.
Pharmaceuticals Buyers & Acquisitions
2 tracked deals by 1315 Capital.
Biotechnology Buyers & Acquisitions
1 tracked deal by 1315 Capital.
Acquisitions in California
4 tracked deals by 1315 Capital.
Acquisitions in New Jersey
3 tracked deals by 1315 Capital.
Acquisitions in Pennsylvania
2 tracked deals by 1315 Capital.
Acquisitions in Florida
1 tracked deal by 1315 Capital.
Selling a company? Get in front of buyers like 1315 Capital
Turn tracked acquisition activity into an outreach-ready buyer list.